Cargando…
Blood–brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s disease
BACKGROUND: Aggregation of the amyloid-β (Aβ) peptide in the brain is one of the key pathological events in Alzheimer’s disease (AD). Reducing Aβ levels in the brain by enhancing its degradation is one possible strategy to develop new therapies for AD. Neprilysin (NEP) is a membrane-bound metallopep...
Autores principales: | Rofo, Fadi, Metzendorf, Nicole G., Saubi, Cristina, Suominen, Laura, Godec, Ana, Sehlin, Dag, Syvänen, Stina, Hultqvist, Greta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720954/ https://www.ncbi.nlm.nih.gov/pubmed/36471433 http://dx.doi.org/10.1186/s13195-022-01132-2 |
Ejemplares similares
-
Enhanced neprilysin-mediated degradation of hippocampal Aβ42 with a somatostatin peptide that enters the brain
por: Rofo, Fadi, et al.
Publicado: (2021) -
A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer’s Disease Mice
por: Rofo, Fadi, et al.
Publicado: (2022) -
Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta
por: Rofo, Fadi, et al.
Publicado: (2021) -
Development of brain-penetrable antibody radioligands for in
vivo PET imaging of amyloid-β and tau
por: Banka, Vinay, et al.
Publicado: (2023) -
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein
por: Bonvicini, Gillian, et al.
Publicado: (2022)